NCT05249816 - Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine | Biotech Hunter

Enrollment

1,000

Participants

Timeline

Start Date

March 18, 2022

Primary Completion Date

May 4, 2023

Study Completion Date

May 4, 2023

Conditions

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Interventions

BIOLOGICAL

NVX-CoV2373

A single booster injection of NVX-CoV2373 with Matrix-M adjuvant. 0.5 mL injection volume at a dose of 5μg of antigen with 50 μg Matrix-M adjuvant

BIOLOGICAL

BBIBP-CorV vaccine

BBIBP-CorV vaccine administered per manufacturer instructions.

Trial Locations (2)

Cleveland Clinic Abu Dhabi, Abu Dhabi

Sheikh Khalifa Medical City (SKMC), Abu Dhabi